Sonic Incytes_Secondary_Colour.jpg
Sonic Incytes Announces FDA Clearance and US Launch of Velacur™ to Help Manage Emerging Health Crisis
October 20, 2020 10:00 ET | Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver...
National Lipid Association Announces Recipients of 2018-19 Junior Faculty Research Awards
July 06, 2018 13:00 ET | National Lipid Association
JACKSONVILLE, Fla., July 06, 2018 (GLOBE NEWSWIRE) -- The National Lipid Association announced on Friday the recipients of its 2018-19 Junior Faculty Research Awards for Clinical Science and Basic...
IMC Logo.jpg
Immuron Granted US Patent for NASH Treatment
November 15, 2017 09:00 ET | Immuron Limited
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...
galectin.jpg
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
November 13, 2017 09:00 ET | Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D.,...
galectin.jpg
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update
November 07, 2017 08:15 ET | Galectin Therapeutics Inc.
All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expected to be...